TY - JOUR ID - 10281 TI - Denosumab in Patients with Giant Cell Tumor and Its Recurrence: A Systematic Review JO - The Archives of Bone and Joint Surgery JA - ABJS LA - en SN - 2345-4644 AU - Jamshidi, Khodamorad AU - Gharehdaghi, Mohamad AU - Hajialiloo, Sami Sam AU - Mirkazemi, Masoud AU - Ghaffarzadehgan, Kamran AU - Izanloo, Azra AD - Bone and Joint Reconstruction Research Center, Shafa Orthopedic Hospital, Iran University of Medical Sciences, Tehran, Iran AD - Orthopedic Research Center, Mashhad University of Medical Sciences, Mashhad, Iran AD - Razavi Cancer Research Center, Razavi Hospital, Imam Reza International University, Mashhad, Iran Y1 - 2018 PY - 2018 VL - 6 IS - 4 SP - 260 EP - 268 KW - Denosumab KW - Giant cell tumor of bone KW - Meta-analysis KW - Recurrence KW - Systematic review DO - 10.22038/abjs.2018.25254.1665 N2 - Recent studies suggest that Denosumab reduces tumor size, therefore, makes the surgery easier with lowermorbidity. However, some studies have reported several complications for this drug. So, this systematic reviewwas performed to determine the effectiveness and safety of Denosumab in reducing bone destructions activity ofgiant cell tumor and skeletal-related events (SRE) in affected patients with giant cell tumor of bone (GCTB) and itsrecurrence.We explored studies in PubMed, and Cochrane Library. For this purpose, articles of various levels were retrieveduntil October 22, 2016. Two reviewers assessed the articles independently based on predefined criteria to extract therelevant data. Primary outcomes associated with skeletal-related event, overall survival, and secondary outcomessuch as pain, quality of life and adverse events were evaluated and analyzed.The total population of this meta-analysis consisted of 686 patients. Of this population, 55% had primary GCTB and45% had giant cell tumor recurrence, with 2% experiencing secondary recurrence.The results showed the effectiveness of Denosumab in reducing the tumor size due to inhibiting the Osteoclastogenesis.Denosumab didnot show any effect on reducing tumor recurrence, but, in cases where complete tumor surgery isnot possible and tumor residuals may remain, Denosumab can be helpful. Also, the clinicians should consider therisk benefit of Denosumab. UR - https://abjs.mums.ac.ir/article_10281.html L1 - https://abjs.mums.ac.ir/article_10281_8ddf02811d1e1346c38db38ef7df7d64.pdf ER -